Precision Health Reports

Big news for anyone who orders Precision Health Reports for their patients or for themselves.

In March 2026, the ACC and AHA published the most important update to cardiovascular risk guidelines in nearly ten years. These are the standards that determine who should be on cholesterol-lowering medication, what their treatment targets should be, and which risk factors deserve serious attention.

As of May 1, 2026, every Precision Health Reports Cardiometabolic Risk Assessment fully reflects every change in this new guideline. Here are the highlights:

✅ The risk calculator that determines your 10-year heart risk has been updated to PREVENT which is a more accurate tool that accounts for kidney function and blood sugar alongside traditional risk factors. We adopted this in December 2025, before it became the standard.

✅ The threshold for "high risk" was cut in half. Patients who scored between 10–19% on the old scale and were told they were intermediate risk now formally qualify for more aggressive prevention.

✅ Women's cardiovascular risk factors are now more complete. Conditions like preeclampsia, gestational diabetes, premature menopause, and PCOS are now explicitly recognized in the guidelines and captured in our updated assessment questionnaire.

If you've ordered an Assessment recently, the report they received already reflects these updated standards.

Full details here 👇

precisionhealthreports.com

Most people show up to their doctor with a "normal, but maybe a little high" LDL-cholesterol and leave thinking they're fine.

But LDL-C is a mass measurement. It tells you how much cholesterol is riding in your LDL particles—not how many particles are carrying it.

That distinction matters. A lot.

Particle number (ApoB) predict cardiovascular events in people with metabolic dysfunction, insulin resistance, and diabetes—populations where discordance between LDL-C and ApoB is common.

When LDL-C looks normal but particle count is elevated, you're looking at residual risk that standard panels miss entirely.

Doctors who measure ApoB find what the lipid panel leaves behind.

If you don't get a Cardiometabolic Risk Assessment, at least as your primary care to measure your ApoB at your next exam.

ApoB vs LDL-C: Why Particle Count Predicts Risk Better | Precision Health Reports LDL cholesterol alone can miss hidden risk. See how ApoB particle count provides even clearer insight for heart disease prevention.

Insulin resistance often shows up in your labs years before a diabetes diagnosis. Insulin resistance is the key linkage between metabolic and cardiovascular health.

Most tests don't catch changes in insulin resistance early enough.

LP-IR, the lipoprotein insulin resistance score, is one of the most validated early markers available.

Here's how it compares to HOMA-IR, fasting insulin, and other common methods.

LP-IR vs. Fasting Insulin: Why LP-IR Is the More Reliable Measure | Precision Health Reports Fasting insulin is highly variable. See why the LP-IR score, derived from NMR lipoprotein patterns, is a more reliable measure of insulin resistance.

Have you ever been told your labs look "normal", but you still don't feel right?

Cardiometabolic disease is one of the most common and under-detected conditions in the US.

It's not a single diagnosis. It's a cluster of metabolic and cardiovascular conditions that share one root cause: insulin resistance.

We wrote a thorough, plain-language guide to help you understand what it is, how it develops, and what a real personal assessment looks like.

https://precisionhealthreports.com/what-is-cardiometabolic-disease

We'd love to hear your questions in the comments.⬇️

What Is Cardiometabolic Disease? — Precision Health Reports Cardiometabolic disease is not a single condition. it is a system of interconnected metabolic and cardiovascular disorders, all sharing a common root cause. Understanding that root cause changes how you measure, prevent, and treat it.